CIK 0001607678 · Large accelerated filer
Viking Therapeutics, Inc.
Sign in to watch- Ticker
- VKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 461073877
- Phone
- 858-704-4660
- Business address
- 9920 PACIFIC HEIGHTS BLVD, SUITE 500, SAN DIEGO, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-01-19 | Lian Brian President & CEO | Shares withheld for taxes | −4,333 | $8.78 | $38K | 1,560,152 |
| 2019-01-03 | MORNEAU MICHAEL VP, Finance and Administration | Grant or award · Stock Option (Right to Buy) | +29,000 | 29,000 | ||
| 2019-01-03 | Masamune Hiroko Chief Development Officer | Grant or award | +22,667 | 141,063 | ||
| 2019-01-03 | Masamune Hiroko Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +66,000 | 66,000 | ||
| 2019-01-03 | Lian Brian President & CEO | Grant or award | +80,897 | 1,564,485 | ||
| 2019-01-03 | Lian Brian President & CEO | Grant or award · Stock Option (Right to Buy) | +235,554 | 235,554 | ||
| 2019-01-02 | Webster Stephen W Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2019-01-02 | SINGLETON J MATTHEW Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2019-01-02 | FOEHR MATTHEW W Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2019-01-02 | MACARTNEY LAWSON Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2019-01-02 | Rowland Charles A Jr Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2018-09-25 | LIGAND PHARMACEUTICALS INC 10% owner | Sale | −262,881 | $19.15 | $5.0M | 6,038,083 |
| 2018-07-01 | Masamune Hiroko Chief Development Officer | Grant or award | +15,000 | 111,197 | ||
| 2018-07-01 | Masamune Hiroko Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +42,000 | 42,000 | ||
| 2018-05-31 | SINGLETON J MATTHEW Director | Purchase | +9,500 | $9.82 | $93K | 9,500 |
| 2018-05-31 | MORNEAU MICHAEL VP, Finance and Administration | Sale | −21,551 | $9.25 | $199K | 94,035 |
| 2018-05-29 | Rowland Charles A Jr Director | Purchase | +30,000 | $5.16 | $155K | 30,000 |
| 2018-05-29 | Webster Stephen W Director | Purchase | +8,000 | $5.21 | $42K | 8,000 |
| 2018-05-29 | MACARTNEY LAWSON Director | Purchase | +47,965 | $5.22 | $250K | 47,965 |
| 2018-05-21 | LIGAND PHARMACEUTICALS INC 10% owner | Other disposition · Convertible Note (convertible into Common Stock) | −1,916,509 | $1,916,509.00 | $3673.0B | 0 |
Page 23 of 27 · 528 trades